Last reviewed · How we verify
Antipyretic
Antipyretic is a Small molecule drug developed by Ultragenyx Pharmaceutical Inc. It is currently in Phase 3 development. Also known as: paracetamol, acetaminophen, ibuprofen.
Antipyretics are substances that reduce fever by causing the hypothalamus to override a prostaglandin-induced increase in temperature. Examples of antipyretics include small molecule compounds such as acetanilide, which is a synonym for some antipyretics.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antipyretic |
|---|---|
| Also known as | paracetamol, acetaminophen, ibuprofen |
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Effect of Acetominophen an Gait Fatigue in Multiple Sclerosis
- Antipyretic Therapy With and Without Cold Sponging (NA)
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza (PHASE2)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia (PHASE4)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- USING A DECISION-MAKING SYSTEM TO SUPPORT THE MANAGEMENT OF FEVER AND ACUTE PAIN IN CHILDREN (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antipyretic CI brief — competitive landscape report
- Antipyretic updates RSS · CI watch RSS
- Ultragenyx Pharmaceutical Inc portfolio CI
Frequently asked questions about Antipyretic
What is Antipyretic?
Who makes Antipyretic?
Is Antipyretic also known as anything else?
What development phase is Antipyretic in?
Related
- Manufacturer: Ultragenyx Pharmaceutical Inc — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: paracetamol, acetaminophen, ibuprofen
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing